Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.
Two granulocytopenic patients in whom fungemia persisted despite therapy with deoxycholate amphotericin B were subsequently successfully treated by daily intravenous administration of amphotericin B entrapped in sonicated liposomes made of egg yolk lecithin, cholesterol and stearylamine in a molar ratio of 4:3:1. High serum concentrations of amphotericin B could be maintained in both patients during therapy with liposomal amphotericin B and were associated with high in vitro antifungal activity. Liposomal amphotericin B was tolerated much better than the deoxycholate preparation. These findings suggest that the liposomal amphotericin B preparation is superior in the treatment of fungemia in granulocytopenic patients, and that randomized trials are warranted.
Sculier
J P
JP
H. J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
Bron
D
D
Coune
A
A
Meunier
F
F
D000380:Agranulocytosis / Q000150:complications; D000666:Amphotericin B / Q000008:administration & dosage*; D002177:Candidiasis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004337:Drug Carriers; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B